Tony Kouzarides
| Tony Kouzarides | |
|---|---|
| Born | 17 January 1958 |
| Fields |
Cancer Chromatin Transcription |
| Institutions |
University of Leeds University of Cambridge Gurdon Institute New York University Laboratory of Molecular Biology Abcam |
| Alma mater |
University of Leeds (BSc) University of Cambridge (PhD) |
| Thesis | A molecular analysis of transformation by human cytomegalovirus (1985) |
| Doctoral advisor | Tony Minson |
| Doctoral students | Jacqui Sutherland Helen Brown Juliet Reid Klaus Martin Eric Miska Philip Zegerman Wendy Bergers Dan Wolf Graeme Cuthbert Karen Halls Claire Pike |
| Other notable students | (postdocs) Christian Hagemeier Didier Trouche Jonathan Milner Alex Brehm Catherine Le Chalony Søren Neilson Paul Lavender Francois Fuks Marian Martinez Balbas Laurence Vandel Uta-Maria Bauer Guida Ruas Emma Langley Sylvain Daujat Luke Hughes-Davies Robert Schneider Steve Sanders Susana Lopes Chris Nelson Paul Hurd Sopie Deltour David Lando Antonis Kirmizis Hatice Akarsu Blerta Xhemalce Till Bartke Marc Schneider Gonçalo Castelo-Branco |
| Notable awards |
Heinrich Wieland Prize (2013) Fellow of the Royal Society (2012) FMedSci (2001) |
|
Website www royalsociety |
|
Tony Kouzarides, FMedSci,FRS (born 17 January 1958) is the deputy director of the Gurdon Institute, a founding non-executive director of Abcam and a Professor of Cancer Biology at the University of Cambridge.
Kouzarides was educated at the University of Leeds, graduating with a Bachelor of Science degree in Genetics in 1981. He went on to complete his PhD at the University of Cambridge in 1985.
Following his PhD, Kouzarides did postdoctoral work at the Laboratory of Molecular Biology (LMB) on the cancer potential of cytomegalovirus. and then on to New York University Medical Center. Here he examined the c-Fos leucine zipper dimerisation domain to elucidate its function. He got a job at the Gurdon Institute in Cambridge, where he has been since.
Kouzarides is a leader in the field of chromatin modification and its role in transcriptional control and cancer. In 1996 he made a key discovery in finding that the transcriptional co-activator CBP is a histone acetyltransferase. He has since worked on identifying several new histone modifications, describing their functions in transcription and DNA repair and highlighting their mis-regulation in cancer. His demonstration that a histone acetylation pathway inhibitor can be used to treat MLL-leukaemias has facilitated its use in clinical trials.
...
Wikipedia